Nonesmall-cell lung cancer (NSCLC) patients inevitably progress to first-line therapy and further active treatments are warranted. In the past few years, new second-line therapies, beyond chemotherapy agents, have become available in clinical practice. To date, several options for the second-line treatment of noneoncogene-addicted NSCLC patients ranging from chemotherapy in combination with antivascular endothelial growth factor receptor to immunotherapeutics are available. In oncogene-driven tumors, the better knowledge of mechanisms of acquired resistance to earlier tyrosine kinase inhibitors is leading to novel active inhibitors now available/in development. The second-line algorithm treatment of NSCLC becomes very intricate and the selection of proper patients with one of the new available therapeutic options is of paramount importance to personalize and optimize the treatment. In this review we discuss the second-line treatment opportunities of addicted as well as not-addicted NSCLC.
Introduction
Nonesmall-cell lung cancer (NSCLC) represents 85% of all new lung cancer diagnoses and includes different histologic subtypes: adenocarcinoma, squamous cell, and large-cell carcinoma. 1 Most patients had advanced disease at diagnosis and palliative treatments are the standard of care. In the presence of oncogene-addicted NSCLC, new agents are developed in the past decades as first-line therapies, using correspondent inhibitors of epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-kinase ROS (ROS1). Without any of those genetic alterations, the standard first-line treatment is platinumbased chemotherapy consisting of an induction phase for 4 to 6 cycles, and of maintenance phase, either switch or continuation maintenance for nonsquamous histology. The recent approval by Food and Drug Administration (FDA) and European Medicine Agency (EMA) of the immune agent pembrolizumab as first-line treatment for advanced NSCLC patients with programmed deathligand 1 (PD-L1) tumor proportion score (TPS) !50% has expanded therapeutic options for wild type NSCLC patients. Unfortunately, disease progression occurs in all patients and active treatment is needed.
Materials and Methods
The International Experts Panel Meeting on second-line treatment of NSCLC was held on May 12, 2017 , in Sperlonga, Italy. Thirteen medical oncologists (4 from Italy, 3 from the United States, 3 from France, 2 from Spain, and 1 from The Netherlands) formed the scientific panel. Published data useful for panel discussion were identified using a PubMed search, performed with combinations of the following search terms: "nonesmall-cell lung cancer" and "second-line treatments." Only articles written in English were considered. For the discussion, each panelist selected the references that were considered relevant to the assigned topic. Abstracts presented between 2000 and 2017 at the main international meetings also were searched. The search has been updated for this article with the proceedings of the 2017 American Society of Clinical Oncology meeting. Relevant references from selected articles also were included, and other articles were selected from the personal collections of the panelists. The level of evidence and the strength of recommendation have been evaluated according to Center for Disease Control and Prevention grading system. 2 
Treatment of Wild Type Patients
Old and New Chemo-and Antiangiogenetic Agents in the Second-Line Setting Several options are approved for use in the second-line setting or more: docetaxel alone and in combination with ramucirumab or nindetanib (the last one in adenocarcinoma only, but not approved in the United States), and pemetrexed as a single agent for nonsquamous histology only.
First, docetaxel was approved as a second-line option on the basis of its superiority compared with supportive care or control regimen (vinorelbine or ifosfamide), nearly 17 years ago. 3, 4 Since then, comparable efficacy outcomes and significantly fewer side effects for pemetrexed over docetaxel were reported, with its approval by the US Food and Drug Administration (FDA) in 2004 as second-line therapy for any histologies first, and later narrowed to nonsquamous only. 5 However, the median survival remains poor and not longer than 8 months, with only one-third of patients alive at 1 year. The increased responses achieved with the combination of chemoagents as second-line strategies did not correlate to significant improvement of survival outcomes, confirming single-agent chemotherapy as the standard for a large proportion of pretreated patients. 6 New interesting combinations of a taxane drug to a vascular endothelial growth factor (VEGF) pathway inhibitor favored over docetaxel alone, with statistically significant but clinically only modest improvement in survival. In particular, the additional use of the monoclonal antibody ramucirumab with docetaxel increased responses (objective response rate [ORR], 22.9% vs. 13.6%) and prolonged progression-free survival (PFS; hazard ratio [HR] , 0.76) and small overall survival (OS) benefit (HR, 0.86). 7 To note, a small proportion of patients having received bevacizumab in the first-line setting were also included. The small OS improvement, although statistically significant, was consistent across histologies, with benefit in squamous as well as nonsquamous NSCLC patients, because the study was not stratified accord to histology (in contrast to most bevacizumab studies enrolling squamous only) and not powered to show survival benefit for each histological subgroup. Interestingly, the effect of ramucirumab with docetaxel was approximately the same across patients with refractory disease (progression as best response to first-line treatment) and intention to treat (ITT) population. 8 This REVEL trial led to FDA approval of ramucirumab in combination with docetaxel regardless of histological subtype. Similarly, weekly paclitaxel in combination with bevacizumab confirmed the superiority to docetaxel in pretreated nonsquamous patients. 9 Approximately 30% of patients in the trial had received bevacizumab as first-line and 2 previous lines of therapy. The ULTI-MATE study met its primary end point with a significant improvement of PFS (median PFS, 5.4 vs. 3.9 months for combination and singleagent arm, respectively; HR, 0.62). The allowed crossover between 2 arms at progression probably explained the absence of OS benefit (HR, 1.18), but showed the benefit of the combination after progression with docetaxel treatment. 10 However, this combination is not approved for use in clinical practice by regulatory agencies. Nindetanib, a multitarget tyrosine kinase inhibitor (TKI), in association with docetaxel as second-line treatment improved PFS across histologies of patients enrolled in the LUME-Lung 1 trial. The small but significant magnitude of PFS benefit (HR, 0.79) was not associated with OS improvement in all population (HR, 0.94), but only for the adenocarcinoma subgroup, with 2.3 months increase of median survival (HR, 0.83). 11 Nindetanib remained active in patients with refractory disease, with an impressive improvement of median survival of >3 months, despite the small number of patients in subgroup analysis.
Comparing phase III trials, the magnitude of PFS and OS benefits for nonsquamous NSCLC pretreated patients was similar across all 3 antiangiogenetic agents (ramucirumab, nindetanib, and bevacizumab) when used in combination with taxanes. The main issue with an anti-VEGF receptor (VEGFR) therapy is the short duration of benefit, probably because of mechanisms of resistance, above all the activation and the upregulation of alternate proangiogenic pathways (such as hypoxia-inducible factor-1 alpha) with a potential shift to an aggressive phenotype of tumor cells.
Another promising prospect is to use antiangiogenic drugs targeting VEGF-A/VEGFR in combination with immune agents, with the aim to reduce the immunosuppressive effects of this axis inhibition (restoration of proportion and maturation of dendritic cells, decrease of myeloid-derived-suppressor cell number in tumors, inhibition of regulatory T cells accumulation, and increase of CD4-positive [CD4 þ ] and CD8 þ T cells in tumors). Preliminary data from phase Ia study of ramucirumab with pembrolizumab suggested activity in pretreated patients with solid tumors regardless of PD-L1 status. 12 In conclusion, antiangiogenic drugs targeting the VEGF pathway have achieved success in combination with chemotherapy exploiting the concept of "vascular normalization," including antibodies to VEGF-A (bevacizumab as first-and second-line) or to VEGFR-2 (ramucirumab as second-line) and only 1 VEGFR-TKI
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Second-Line Treatment Options in NSCLC (nindetanib as second-line). In the second-line setting, there is a consistent improvement of PFS, but modest magnitude of OS benefit, probably because of a short duration of effect, with still no predictive biomarker. Interestingly, the activity was maintained in refractory patients, suggesting their role for this subgroup of patients.
The Role of TKIs in EGFR Wild Type
After the first approval in 2005 as one of the standards in secondline therapy, in the recent past EGFR-TKIs showed less PFS efficacy compared with docetaxel in EGFR wild type patients but showed an advantage in tolerability and quality of life. Analyzing the cost/ benefit balance, in the past 5 years the costs of these drugs were evaluated as too high to be considered a standard in this setting. 13 To date, erlotinib still represents a potential option in pretreated patients with unknown or wild type EGFR status (not in the United States where it is no longer approved by the FDA) and preferably in patients not suitable for chemotherapy, but to date with a very limited use in clinical practice. [14] [15] [16] [17] [18] An additional option could be represented by afatinib, mainly for patients with performance status (PS) of 0 to 2 with locally advanced squamous-cell carcinoma progressing during or after platinum-based chemotherapy but the drug has not been approved by regulatory agencies.
14,19
The Role of Immunotherapy: Anti-Programmed Cell Death Protein 1 and AntiePD-L1 Agents
Chemotherapy is no longer standard second-line therapy in most patients with NSCLC. Several immune-modulating drugs have been developed, with different dosing, duration of infusion time, and duration of treatment. Two classes of drugs have been developed: antiprogrammed cell death protein 1 (PD-1) and antiePD-L1 agents.
AntiePD-1 Agents: Nivolumab and Pembrolizumab. Nivolumab, an immune checkpoint inhibitor that targets PD-1, is currently approved by the US FDA and European Medicine Agency (EMA) as second-line therapy for squamous as well as nonsquamous advanced NSCLC.
In terms of efficacy, the initial data on nivolumab came from a phase Ib dose-ranging study (CA209-003), in which nivolumab as monotherapy at 3 different doses (1, 3, and 10 mg/kg given intravenously every 2 weeks for <96 weeks) was administered to 129 heavily pretreated NSCLC patients, mainly in the second-/third-line setting. There was reported an ORR of 17%, without major differences between the 2 histologies. To note, the responses were not delayed, occurring at first tumor evaluation (8 weeks) in half of the cases, similar to chemotherapy responders. If they did happen, responses were long-lasting, and the true "pseudo-progressions" were very rare events. 20 Median OS was 9.9 months and an impressive 5-year survival rate of 16% was recently reported, quadrupling the survival rate obtained with standard chemotherapy. 21 These longterm survival rates were consistent across histologies, and more frequently in patients who were initially responders to the immune therapy. Concerning the potential predictive role of PD-L1 status, the 5-year survival rates increased according to PD-L1 increasing levels (5-year OS rate for PD-L1 <1%, !1%, and >50%: 20%, 23%, and 43%, respectively), but the lack of adequate samples for PD-L1 assessment in approximately 50% of patients did not allow its clear validation. 21 Similar activity (ORR, 15%) was assessed in 117 squamous refractory NSCLC patients treated with nivolumab at 3 mg/kg biweekly as third-line or more therapy (Check-Mate 063). A poor median PFS of 2 months happened in this unselected population, and no difference of OS between varying degrees of PD-L1 expression in tumor specimens was reported in the exploratory analyses of this small trial. 22 In the squamous phase III Check-Mate 017 trial, nivolumab as second-line monotherapy showed an improvement in median survival of 3 months (OS as primary end point) compared to docetaxel arm (median OS, 9.2 vs. 6 months with nivolumab and docetaxel, respectively; HR, 0.59). 23 The updated survival data at 2 years confirmed the fork across the curves, with 25% of patients treated with nivolumab still alive. 24 Analyzing the data in terms of PD-L1 expression levels (predefined subgroups using 1%, 5%, and 10% as cutoffs), there was not an effect on the survival outcomes. With similar study design, the Check-Mate 057 trial was conducted with 582 nonsquamous NSCLC patients. 25 In this larger cohort (good PS of 0-1; as second-line treatment after 1 platinum-based chemotherapy; as third-line treatment allowed only for patients with oncogenic mutated NSCLC), the response rates again improved (ORR, 19% vs. 12% for nivolumab and docetaxel, respectively), similarly to squamous data (ORR, 20% 26 Although the study was not designed or powered to prospectively evaluate TPSs, the survival benefit might be started from !10% of PD-L1 expression status.
An interesting analysis about clinical data suggested a higher risk of death with nivolumab than with docetaxel therapy in patients with more aggressive disease (<3 months since last treatment, progressive disease as the best response to the previous treatment, and PS of 1) combined with low or no tumor PD-L1 expression. However, cautions for clinical data interpretation is due, considering the limits of the analysis' nature (retrospective, post hoc, and unplanned) and considering that most of the patients with the worst prognostic factors are not doing well with any treatment, not only with immunotherapy. 27 Another group of patients not benefiting from nivolumab were those EGFR-mutated and never-smokers, probably because of fewer genomic alterations of those tumor cells, thereby to the negativity of PD-L1 status. Not least, a better toxicity profile of nivolumab than docetaxel was reported (lower frequency of Grade 3-4 adverse events [AEs], 10% vs. 50%; AEs leading to treatment discontinuation: 5% vs. 15%). Pembrolizumab is approved by FDA and EMA as treatment for previously treated advanced NSCLC patients with PD-L1 TPS !1%, unlike the first-line approval (PD-L1 TPS !50%). The anti PD-L1 pembrolizumab (registered dose: 2 mg/kg every 3 weeks) is a fully human monoclonal immunoglobulin (Ig)G4 k antibody with an impressive half-life of 14 to 27 days.
The phase Ib Keynote 001 is the first trial to evaluate pembrolizumab in 550 advanced NSCLC patients (101 treatment-naive, and 449 pretreated). Recently, 3-year survival outcomes of the trial confirmed the efficacy of pembrolizumab for first-line as well as previously treated advanced NSCLC patients expressing PD-L1 (26% and 19% alive at 36 months for untreated and pretreated patients, respectively). 28 The Keynote 010 trial tested 2 different doses of pembrolizumab (at 2 mg/kg and at 10 mg/kg, every 3 weeks) compared with docetaxel in PD-L1 þ patients (PD-L1 expression level >1%): an improvement of OS was significantly reached in all populations (HR 0.71 and 0.61 for 2 mg/kg and 10 mg/kg doses, respectively), as well as in strongly positive patients (PD-L1 expression level >50%), with better results in those last patients (HR, 0.54 and 0.50 for 2 mg/kg and 10 mg/kg doses, respectively). 29 The proportional linkage of pembrolizumab efficacy and PD-L1 TPS was confirmed beyond first-line treatment above all. The superiority of pembrolizumab remains confirmed from updated data after 1 more year of follow-up, doubling rates of patient survivors at 2 years and with an apparent plateauing of the OS curves. 30 Recently, exploratory post hoc multivariate analyses showed that some laboratory (normal baseline lactate dehydrogenase), and tumor characteristics (nonsquamous histology, PD-L1 TPS !50%, and wild type EGFR mutation status) were associated with better OS among patients treated with pembrolizumab. 31 Concerning the small sample of 47 patients who stopped pembrolizumab treatment after a preplanned 2 years per protocol, the chance of having progression in the following 9 to 10 months was approximately 4%. If the treatment should continue or not, and if a delayed every 4 weeks schedule could be used as maintenance after an induction phase are questions still open. 32 As new combination strategies beyond first-line therapy, preliminary phase I/II results of ECHO-202/KEYNOTE-037 (NCT02178722) were recently presented about epacadostat (an indoleamine 2,3-dioxygenase pathway inhibitor) with pembrolizumab: the ORR and disease control rate (DCR) were 35% (14 of 40; 14 partial response) and 60% (24 of 40; 10 stable disease), respectively.
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AntiePD-L1 Agents: Atezolizumab, Durvalumab, and Avelumab. Two main differences are between PD-1 and PD-L1 agents: first, the type of targets (antiePD-L1 agents inhibit the PD-L1/PD-1 and PD-L1/B7.1 interactions) 33 ; second, anti-PD-L1 agents leave the PD-L2/PD-1 interaction intact, thereby potentially preserving peripheral immune homeostasis, but few preclinical data are available to date. The antiePD-L1 atezolizumab is the most recent immune agent approved as second-line treatment in advanced NSCLC. From phase I trials, different pharmacokinetic profiles of atezolizumab resulted in different ethnicity patients, with longer elimination half-life for Caucasian than for Japanese patients (21-23 days and 11-13 days, respectively). 33, 34 The phase II Birch Trial included only patients whose tumors expressed PD-L1 using the Ventana SP142 immunohistochemistry (IHC) assay (Ventana Medical Systems, Inc, Tucson, AZ) on !5% of tumor cell (TC) membranes or immune cell (IC) membranes, classified as TC 2/3 or IC 2/3: the efficacy-evaluable patients received atezolizumab at 3 different lines of treatment (cohort 1 as first-line, cohort 2 as second-line, and cohort 3 as third-line or higher) at the standard dose of 1200 mg intravenously every 3 weeks. In terms of activity, the ORR reported for first-line treatment (22%) was similar to those reported in subsequent lines (ORR of 19% and 18% for cohorts 2 and 3, respectively) with higher responses according to TC 3 or IC 3 (ORR, 31%, 26%, and 27% for each cohort subgroup, respectively). Responses occurred regardless of EGFR or KRAS mutation status. Disease progression occurred at a median of 2.8 months for the 2 pretreated cohorts, and >4 months in the favorable subgroup of TC 3 or IC 3 patients. From an updated survival analysis (minimum of 20 months of follow-up), the median OS for untreated patients was 23.5 months (26.9 months for TC 3 or IC 3 patients), whereas the median OS in the 2 pretreated cohorts was 15.5 and 13.2 months, respectively. 35 The approval by the FDA of atezolizumab as a second-line option was on the basis of improved survival data from a large phase III randomized clinical trial (OAK), in which atezolizumab was compared with docetaxel. After the gain in survival of 2.9 months achieved in the randomized phase II POPLAR trial, 36 the larger phase III OAK trial enrolled 1225 pretreated NSCLC patients, independently of PD-L1 expression status (centrally evaluated on TCs and ICs with the Ventana SP142 IHC assay). The survival data about the primary population, consisting of the first 850 patients enrolled, were analyzed for the ITT and for PD-L1 þ population (TC 1/2/3 or IC 1/2/3), both coprimary end points. 36 For baseline characteristics of the primary population, EGFR-mutated patients and those with brain metastases represented approximately 10%, whereas squamous patients or those who received more than 1 line of chemotherapy represented onequarter of the population. After a median follow-up of 21 months, a significant survival improvement was reached in the ITT population, with a reduction of death risk of 27% (HR, 0.73; P ¼ .0003) and an increase by 4 months in the median OS (13.8 months in the atezolizumab arm vs. 9.6 months in the docetaxel arm), whereas PFS was numerically favorable in the docetaxel arm. In the TC1/2/3 or IC1/2/3 population, median OS was 15.7 months among 241 patients receiving atezolizumab versus 10.3 months among 222 patients receiving docetaxel (HR, 0.74, P ¼ .0102), translating to an increase of >5 months in the median survival of those patients (median OS, 15.7 months vs. 10.3 months). A significant 25% improvement in survival was reported among patients with negative PD-L1 expression (TC 0 or IC 0), differing from nivolumab data, and suggesting benefit irrespective of PD-L1 expression level. 37 The meaning of those PD-L1
À results have to be clarified, considering that the antibody used for IHC (Ventana SP142) was performed somewhat differently from the 3 others in use, as established in the Blueprint study. 38 In addition, atezolizumab was more efficacious than docetaxel in all predefined subgroups, reducing the risk of death by 18% to 65%, regardless of how PD-L1 status was assessed (IHC vs. gene expression) and in patients differing with respect to tumor histology, age, smoking status, and presence of central nervous system (CNS) metastases. The lone exception was noted in patients with EGFR mutations, who did not derive any greater benefit than docetaxel (OS HR, 1.24), as was seen in trials of other antiePD-1 agents. The same survival benefit derived for different histological subgroups across PD-L1 expression levels (HR, 0.73 for squamous and nonsquamous): the shape of curves clearly separated at the same times, despite longer median OS for nonsquamous than for squamous treated with either agent, similar to other trials of nivolumab and pembrolizumab. In terms of activity, higher PD-L1 expression levels seem to correlate with greater ORR (31% for TC 3 or IC 3 vs. 8% for TC 0 and IC 0), with no influence on duration of response (DoR). 39 The survival benefit of atezolizumab extended beyond radiographic progression is recently supported by the phase IIII OAK trial, with a median OS postprogression of 12.7 months for the atezolizumab arm compared with 9.7 months for the docetaxel arm. This analysis is from a large cohort (approximately 50% of the atezolizumab arm prolonged the treatment beyond progression), which highlighted the inadequacy of Response Evaluation Criteria in Solid Tumors (RECIST) to capture the full clinical benefit of immunotherapy and supports the concept of immuno-treatment beyond disease progression, but further randomized clinical trials are needed to confirm it. 40 Predictive factors of atezolizumab efficacy are still under investigation. Data from the POPLAR trial have suggested tumor mutation burden (TMB) as a potential predictive factor of atezolizumab efficacy: higher TMB seems to be correlated with better PFS and OS outcomes for patients who received atezolizumab, whereas no effect for patients who received chemotherapy. 41 The interferon-g (INFg)
gene signature and B7.1 expression superior to median seems to favor more atezolizumab than chemotherapy, suggesting a new future prospect. Regarding patients with EGFR activating mutations, there was no difference for immunotherapy compared with chemotherapy outcomes. In the OAK study, the rate of PD-L1 À status (TC 0 or IC 0) was greater for the EGFR-mutant subgroup, probably explaining the lower activity (ORR, 5%) and poorer survival outcomes (HR for OS, 1.24; HR for PFS, 1.21). Therefore, immunotherapy might be detrimental for EGFR-mutant patients, even if the number of those is quite low. Finally, atezolizumab has efficacy and a good safety profile in pretreated patients (independently of PD-L1 expression), possibly also in naive patients (trials ongoing).
Durvalumab, a selective, high-affinity, engineered human IgG1 monoclonal antibody, blocks PD-L1 binding to PD-1 and CD80. The first data coming from a phase I trial showed clinical activity of durvalumab in the NSCLC expansion cohort, with higher ORR in PD-L1 high (!25% of tumor cells) than PD-L1 low-expressing patients (ORR, 25% vs. 6%), irrespective of treatment line, histological subtype, and smoking status. Despite best survival outcomes in the first-line setting, durvalumab showed its work also in pretreated patients, with more than half of those alive at 1 year (OS 1-year rate of PDeL1-high: 56% and 51% for second-and thirdline setting, respectively). 42 Data from the phase II single-arm ATLANTIC trial were recently reported, showing activity in heavily pretreated (third-line or higher) advanced NSCLC patients. The study initially enrolled patients regardless of PD-L1 status, but was later restricted to patients whose tumor expressed PD-L1 at least 25% according to IHC (Ventana SP263 assay). Similar to other agents in this setting, the degree of activity of durvalumab seems related to PD-L1 expression, increasing proportionally to its level of positivity: the ORR was 16.4% and 30.9% in patients with !25% and !90% of tumor cells positive for PD-L1, with both cohorts having EGFR and ALK wild type tumors. Consistent survival outcomes showed half of PD-L1 þ patients still alive at 1 year (1-year OS rate, 47% for PD-L1 !25% and 50.8% for PD-L1 !90%). The main limitation for clinical interpretations is that these are uncontrolled data, so subject to patient selection. If these agents should be used in firstand second-line settings, especially in tumors with high PD-L1 expression, rather than in third-or higher-line monotherapy remains unknown. 43 For the first time, in this trial durvalumab was prospectively evaluated in 111 EGFR-mutated/ALK-rearranged heavily pretreated patients (mean of 4 previous regimens). 44 As a baseline characteristic, this cohort included 87% of EGFR-mutated and 13% of ALK-rearranged patients, mainly never-smokers (58%).
Higher PD-L1 expression (25% cutoff) appeared to be associated with higher ORR, with activity data comparable with those reported for the EGFR/ALK wild type PD-L1 high-expression cohort (ORR, 12.2% and 16.4%, respectively). Analyzing data according to oncogenic alteration, durvalumab seemed to work better for EGFRmutated (ORR,14%; 1-year OS, 57%) than ALK-rearranged patients (ORR, 0%; 1-year OS, 35%), despite limited numbers of the latter. Interestingly, quite encouraging survival results were in the PD-L1 low-/negative-expression patients, with 40% of those alive at 1 year, but the duration of follow-up is still short. 44 In the lung-map design, squamous patients with no matchspecific molecular alterations (EGFR, phosphoinositide 3-kinase, CCCGA) might receive durvalumab or docetaxel at least as secondline treatment: the 16% of the entire study population responded to atezolizumab and higher responders were in the PD-L1 !25% subgroup, according to other previous trials, whereas no differences in the docetaxel arm were reported using durvalumab in PD-L1 low-expression patients. Survival outcomes seemed to favoring atezolizumab over docetaxel (median OS, 11.6 vs. 7.7 months for atezolizumab and docetaxel, respectively), but a higher number of patients, longer follow-up, and more data are needed. 45 After the promising data and impressive response rates (ORR, 78%-92%) reported with the combination of nivolumab with ipilimumab as first-line in higher PD-L1 expression (!25%) NSCLC, another combination of durvalumab and tremelimumab seems promising for pretreated patients. In the dose-escalation phase I study, clinical activity did not appear to be dependent on PD-L1 status. In the combined cohorts of tremelimumab treatment in doses of 1 mg/kg every 4 weeks and durvalumab in doses 10 to 20 mg/kg every 2 or 4 weeks, the ORR was 22% for PD-L1 !25%; quite low compared with impressive data reported using nivolumab and ipilimumab as first-line treatment. However, this combination cohort revealed an impressive activity in PD-L1 low-expression (<25%) and PD-L1 À patients, with an ORR of 29% and of 40%, respectively, suggesting the potential clinical role of tremelimumab combined with durvalumab for those patients. 46 Several phase III trials are investigating the safety and clinical activity of the durvalumab and tremelimumab combination in different lines of treatment and selected populations. Durvalumab has been evaluated in a phase I study enrolling EGFR-mutated patients: the osimertinib/durvalumab combination arm of the TATTON study was interrupted because of an increase in the incidence of interstitial lung disease-like events, whereas the combination with gefitinib as first-line treatment is still ongoing (NCT02088112).
In the large phase I multicohort dose-escalation and doseexpansion JAVELIN trial, preliminary findings for 184 NSCLC pretreated patients unselected for PD-L1 expression and treated with avelumab, another antiePD-L1 agent, reported objective responses in 22 patients only (12%), with median OS of 8 months. Focusing on PD-L1 status (1% as a cutoff for tumor cell staining), longer PFS occurred in patients with PD-L1 þ tumors (PFS at 48
weeks: 21% for PD-L1 þ vs. 5% for PD-L1 À ); in contrast, survival curves approached at 1 year, with no clear differences between the 2 subgroups (1-year OS, 39% vs. 36% for PD-L1 þ and PD-L1 À , respectively). 47 To date, it is difficult to identify which of 3 agents approved for use in the second-line setting (nivolumab, pembrolizumab and atezolizumab) has the greatest efficacy based on the results of the large phase III clinical trials within the limitations of comparing across studies with significant differences.
Treatment of Patients With Activating Mutations
The current standard first-line therapy for oncogene-addicted patients is EGFR-and ALK-TKIs, respectively. However, the true question is how to best manage patients whose disease progresses during first-line treatment. The subsequent strategies include treatment beyond progression or changing of it. The choice between these 2 options should be guided by the type of progression: primary versus acquired, systemic versus oligoprogression, symptomatic versus asymptomatic, rapid versus slow progression, and CNS metastases versus no CNS metastases. In presence of oligoprogressive disease, the use of local therapy, such as stereotaxic ablative radiotherapy, may be used in addition to continuing firstline TKIs. However, a multisite progression might serve as a guide to consider rebiopsy (if possible) at the time of disease progression, to switch to a next-generation TKI tailored to the selected mutation, if present.
Second-Line Treatment for EGFR Mutation-Positive Patients
The mechanisms of therapeutic resistance to EGFR TKIs was classified as primary or acquired resistance. 48, 49 Primary resistance is defined as a "de novo" lack of treatment response and can be mediated by tumor intrinsic factors (such as coexistent genetic alterations in the drug target, coexistent mutations in other signaling genes, and inactivation of proapoptotic pathways), and by patient-specific factors (such as plasma drug levels and drugedrug interactions). Conversely, acquired resistance refers to disease progression after an initial response to the targeted therapy.
The "escape" mechanisms to evade continuous blockade of the target include target modification (target gene amplification such as mesenchymal-epithelial transition (MET) amplification detected in 5%-10% of tumors, "second site" mutation within the target gene mostly T790M detected in 60% of tumors, alternative splicing of the target gene), the emergence of bypass signaling tracks (activation of "compensatory loops" to circumvent the inhibited target), histologic transformation (epithelial-to-mesenchymal transition [EMT], phenotypic change from NSCLC to small-cell lung cancer, approximately 5% of tumors), as well as other less well characterized mechanisms such as increased growth factor production. Of these, the EGFR T790M mutation is the most common mechanism of drug resistance to first-or secondgeneration EGFR-TKIs in patients who have EGFR-mutated lung cancer and, for this reason, it has been more investigated in clinical research. Examples of strategies to overcome acquired resistance include alternative doses or schedules of the targeted inhibitor, development of more potent "next-generation" inhibitors, dual blockade of the initial target with !2 target-specific agents, and combination drug strategies designed to suppress compensatory signaling loops.
48,49
Osimertinib. In the scenario of EGFR T790M mutations, osimertinib is an oral, potent, irreversible EGFR-TKI that is selective for EGFR-TKI sensitizing as well as T790M resistance mutations. Impressive results were reported for osimertinib in patients with EGFR T790M-mutation advanced NSCLC progressing to EGFR-TKI treatment across all dose levels (ranking from 20 to 240 mg once daily) in the phase I dose expansion cohort trial (AURA). 50 The drug was associated with a response rate of 71% with limited skin (rash-grouped terms 37% [no Grade 3] ) and gastrointestinal (diarrhea 35% [Grade 3, 2%]) AEs. The response rate achieved in the phase I trial were confirmed in the AURA study phase II extension component and in the updated analyses of a preplanned pooled analysis of 2 phase II studies (AURA extension and AURA2), providing a high ORR of 62% and 66%, respectively. The median PFS and the proportion of patients progression-free at 1 year were 11 months and 47.5%, respectively, in the pooled analysis. 51, 52 A recent study investigated 143 patients with detectable EGFR mutations at baseline (median allelic fraction for Ex19del: 7.09%; L858R: 3.81%; T790M: 2.12%) enrolled in the AURA phase I study to assess whether changes in the levels of plasma EGFR mutations after osimertinib treatment were associated with clinical outcome. Clearance of plasma EGFR mutations after 6 weeks of osimertinib therapy appears to be associated with improved ORR and median PFS in patients with T790M positive NSCLC. Evidence or lack of such a "plasma response" measured at 6 weeks could, potentially, be used to predict subsequent outcomes of therapy. 53 Results from the first predefined interim analysis of the ongoing ASTRIS study, the largest reported clinical study of osimertinib in T790M þ NSCLC, with 1217 patients from 120 sites, showed clinical activity similar to that observed in the osimertinib clinical trial program (ORR of 64%) with no new safety signals. 54 The AURA3 trial was the confirmatory phase III study, which compared osimertinib (at a dose of 80 mg once daily) with the standard of care platinum-pemetrexed chemotherapy (maintenance pemetrexed allowed) in patients with metastatic EGFR T790M mutation-positive NSCLC who had progressive disease after first-line EGFR TKI therapy. 55 The population evaluated was quite similar to previous studies but patients with CNS metastases were allowed only if asymptomatic; otherwise, a typical population. A total of 419 patients were randomly assigned in a 2:1 ratio (279 patients to osimertinib and 140 patients to platinum-pemetrexed) and the baseline demographic characteristics of patient were well balanced across AURA3 treatment groups, in particular approximately one-third of patients had asymptomatic CNS metastasis previously treated or too small to be treated (33% vs. 36%) and usual mutations consisting of EGFR T790M (99% each one), exon 19 deletion (68% vs. 62%), L858R mutation (30% vs. 32%), other (2% vs. 4%) in osimertinib and chemotherapy groups, respectively. The median duration of PFS (primary end point) was significantly longer with osimertinib than with platinum-based therapy (10.1 vs. 4.4 months; HR, 0.30; P < .001). Osimertinib benefit was observed in all categories, including CNS metastases. The ORR was significantly better with osimertinib than with chemotherapy (70% vs. 31%; P ¼ .015) in 46 patients evaluable for response included in the CNS full analysis set, as well as the median DoR (8.9 vs. 5.7 months in chemotherapy arms) and median CNS PFS (11.7 vs. 5.6 months; HR, 0.32; P ¼ .004).
55,56
The FDA and EMA granted regular approval for osimertinib for the treatment of patients with metastatic EGFR T790M mutationpositive NSCLC whose disease has progressed during or after EGFR TKI therapy.
In clinical practice, the use of plasma EGFR genotyping allows to draw a potential new paradigm. Plasma and tumor genotyping can have complementary roles for T790M testing, in which plasma genotyping could be the initial step and a biopsy for tumor genotyping could be supplementary. If plasma genotype is positive for T790M, this might obviate the need for a biopsy-this predicts for excellent outcomes with osimertinib treatment (ORR, 63%; median PFS, 9.7 months), similar to that observed when treating with osimertinib on the basis of tumor genotyping results (ORR, 62%; median PFS, 9.7 months).
Focusing on CNS disease, up to 40% of patients with EGFR mutation-positive NSCLC might develop CNS metastases over the course of their disease. Patients with CNS metastases treated with EGFR TKIs have shown a lower risk of progression in the CNS compared with chemotherapy. In this field, osimertinib showed a promising activity in CNS response rate and CNS DCR in patients with T790M
þ NSCLC with baseline CNS metastases, after progression after an EGFR TKI not only in the pooled analysis (AURA extension and AURA2) but also in the AURA phase III trial.
52,55
The BLOOM study is assessing the safety, tolerability, and preliminary efficacy of osimertinib 160 mg once daily in 2 cohorts of patients: T790M unselected and T790M þ (using central test). 57 Preliminary results showed a clear activity of osimertinib in leptomeningeal metastases shown in efficacy assessment conducted on 32 patients (41 enrolled): 23 of 32 patients had a 12-week brain image assessment with 10 showing radiological improvement and 13 stable disease. Furthermore, the geometric mean decrease in EGFR-mutant DNA copy was 57% in 22 patients with predose and cycle 2 day 1 cerebrospinal fluid samples. 57 On the basis of the impressive clinical activity of osimertinib, the clinical research is evaluating its role as first-line treatment. Data from expansion cohorts in the phase I AURA study reported high ORR (overall ORR of 77%: 67% in the 80-mg cohort and 87% in the 160-mg cohort) with DCR nearing 100% when osimertinib was administered as first-line treatment. 58 The ongoing phase III double-blind, randomized FLAURA study (NCT02296125) is assessing the efficacy and safety of osimertinib at the dose of 80 mg versus standard of care EGFR TKIs (gefitinib or erlotinib) in treatment-naive patients with locally advanced or metastatic EGFRmutated NSCLC, with PFS as a primary end point in patients with T790M þ or T790M À expression (PFS in patients with tumors harboring T790M is a key secondary objective). The mechanisms of resistance to third-generation EGFR TKIs can be summarized in EGFR-dependent and EGFR-independent, similarly to early-generation TKIs. The first group include the insurgence of a secondary mutation such as C797S (in trans: could be sensitive to combined therapy with first and third generation TKI, cis: resistant), C797G, L798I, E790K, L692V, L781Q, T790M reduction, disappearance, or loss, and EGFR amplification. In the second one (EGFR-independent) are described HER2 amplification, MET amplification, PIK3 catalytic-alpha (PIK3CA) mutations, phosphatase and tensin homolog loss, RAS-mitogenactivated protein kinase (MAPK) pathway activation (KRASmutant, BRAF-mutant, MAPK1/AKT3), fibroblast growth factor (FGF)2-FGF receptor 1 autocrine loop, EMT, NRAS mutant/copy number gain, insulin-like growth factor (IGF)-1 receptor activation, or phenotypic transformation (histological transformation to smallcell lung cancer). 59, 60 Among these, MET amplification (30%) and C797S (22%) were commonly observed: the first seems more common after osimertinib treatment than after first-line TKI treatment and patients seem to benefit from the combination EGFR with MET TKIs. 60 As these new compounds become widely available for clinical use, patients will be treated with multiple lines of EGFR-targeted therapies with increasing frequency. A recent study of an in vivo model of acquired resistance to EGFR inhibitors, tried to define the efficacy of sequential treatment with first-, second-, and third-generation EGFR inhibitors and to investigate the potential role of the Hedgehog (Hh) pathway in the acquisition of cancer cell resistance. Of note, Hh is another pathway recently identified in the EMT setting and responsible for acquisition of resistance to first-generation EGFR TKIs: its activation has been implicated in tumorigenesis, metastasization, and progression along with cancer stem-like cell maintenance and treatment resistance in several types of human cancer. The authors showed that EGFRmutant NSCLC can benefit from continuous treatment with EGFR inhibitors, independently from mechanisms of resistance and showed an important role of Hh in mediating resistance to EGFR inhibitors through the induction of mesenchymal properties. 
Second-Line Treatment for ALK-Positive Patients
The genetic alterations in ALK define a unique subtype of NSCLC that are highly responsive to genotype-directed TKIs, such as crizotinib. Unfortunately, despite this initial sensitivity, the long-term effectiveness of such therapies is limited by the development of resistance (median PFS with first-line crizotinib of 10-11 months). 62 In general, mechanisms of acquired resistance to TKIs are divided into 2 classes, preserving or not the dominance of ALK signaling in the crizotinib resistant-state (ALK-dependent or ALK-independent). First, the target gene itself can be altered either by secondary mutation or by gene amplification of the primary oncogene, limiting the ability of the drug to inhibit the kinase. In the presence of the drug, the kinase remains active and drives aberrant signaling. Second, alternative signaling pathways, or so-called bypass tracks, can be activated in resistant cells, bypassing the need for signaling from the target. Understanding the mechanistic bases for acquired resistance is crucial to developing strategies to overcome (or delay) resistance in the clinic. 63 Furthermore, advanced ALK-positive NSCLC is characterized by a high lifetime risk of CNS metastases and a high frequency of brain metastases at diagnosis, with the CNS being the most common site of disease progression (in approximately 70% of the patients with CNS metastases at baseline). On the contrary, approximately 20% of the patients without CNS metastases at baseline develop new intracranial lesions as manifestation of acquired resistance. 64 Clearly, there is the need to develop drugs that not only can work on mechanisms of acquired resistance to crizotinib but can also provide activity against CNS metastases. For one-third of patients in whom crizotinib resistance is mediated by ALK mutation or amplification, cancers are still addicted to ALK, and therefore, next-generation ALK inhibitors might be effective in reinducing remissions. These next-generation ALK inhibitors are structurally distinct from and more potent than crizotinib. To date, 2 new ALK inhibitors are approved for patients with metastatic ALK þ NSCLC, such as ceritinib (LDK378) and alectinib (CH5424602), whereas brigatinib (AP26113) received accelerated approval by the US FDA.
Ceritinib. Ceritinib (LDK378) is an oral TKI 20 times more potent than crizotinib against ALK in enzymatic assays. Ceritinib inhibits ROS1 and the IGF-1 receptor, although the inhibition of the IGF-1 receptor is less potent than the inhibition of ALK. Unlike crizotinib, it does not inhibit the kinase activity of MET. 65 Ceritinib crosses the bloodebrain barrier in vivo, and shows clinical responses in patients with crizotinib-resistant disease. The ASCEND-1 was an open-label, phase I trial that recruited 255 patients with ALK-rearranged locally advanced or metastatic cancer who had progressed despite standard therapy (163 of 246 ALKrearranged patients were pretreated with an ALK inhibitor, mainly crizotinib) to receive oral ceritinib at the recommended dose of 750 mg/d in the dose-escalation and -expansion phases. 66 For ceritinib ORR of 72% was reported in ALK inhibitor-naive patients and 56%
in ALK inhibitor-pretreated patients with a median DoR of 17 and 8.3 months, respectively. Median PFS was 18.4 months in ALK inhibitor-naive patients and 6.9 months in ALK inhibitor-pretreated patients. Ceritinib showed intracranial activity with a partial response in 6 of 11 patients with brain metastases. Ceritinib treatment was related to serious AEs in 48% of cases: the most common Grade 3/4 laboratory abnormalities were increased alanine aminotransferase (ALT; 30%) and increased aspartate aminotransferase (AST; 10%), whereas the most common Grade 3/4 nonlaboratory AEs were diarrhea, nausea (6% for each), and vomiting (4%).
66
The ASCEND-2 was a phase II trial including ALK-positive NSCLC patients pretreated with chemotherapy (!1 platinum doublet) whose disease progressed 30 days from last treatment with crizotinib. A total of 140 patients received oral ceritinib 750 mg daily: the median DoR as well as the median PFS in all patients (DoR, 9.7 months; PFS, 5.7 months) were similar to those reported for ASCEND-1, regardless the presence or not of brain metastases. 67 The ASCEND-5 was the first phase III study to assess whether the second-generation ALK inhibitor ceritinib was superior to chemotherapy in 231 patients whose disease progressed during crizotinib treatment. 68 Patients were randomized 1:1 to receive therapy with ceritinib (n ¼ 115) or chemotherapy (n ¼ 116, pemetrexed or docetaxel; crossover to ceritinib was allowed). Median PFS (primary end point) was significantly improved with ceritinib compared with chemotherapy (5.4 vs. 1.6 months; HR, 0.49; P < .001). In subgroup analyses, all categories benefit from ceritinib regardless age, race, sex, the presence or not of brain metastases, PS, smoking history, or previous response to crizotinib. Ceritinib increased ORR compared with chemotherapy (39.1% vs. 6.9%). There was no improvement in OS, probably because the patients who crossed over diluted the potential benefit (75 patients with progressive disease crossed over to ceritinib). 68 Consistent with ASCEND-1, ceritinib resulted in a durable median PFS of 16.6 and 18.4 months according to investigator and blinded independent review committee (IRC) in 124 ALK inhibitor-naive patients with ALK þ NSCLC (of whom 54.8% had received !2 previous antineoplastic regimens) enrolled in the singlearm phase II ASCEND-3 study. Whole body response rates were robust, irrespective of the presence of baseline brain metastases. 69 On the basis of the induction of PD-L1 expression due to constitutive oncogenic signaling reported in NSCLC models harboring echinoderm microtubule-associated protein-like 4eALK rearrangements, an ongoing phase I dose-escalation study is exploring whether ceritinib (at 450 mg/d or 300 mg/d) in combination with nivolumab (3 mg/kg intravenously biweekly) might provide sustained clinical benefit to previously treated (ALK inhibitor or chemotherapy) or treatment-naive patients with ALK þ NSCLC. 70 The combination showed activity (confirmed/unconfirmed ORR in ALKi-pretreated: 63%, and 33%; in ALKi-naive: 83% and 70%), however, the protocol will be amended to address observed toxicities: diarrhea (64%), ALT increase (56%), AST increase (44%), and vomiting (42%) were the most common any-grade AEs whereas the most frequent Grade !3 AEs were increases in ALT (22%), gamma-glutamyltransferase (17%), amylase (11%), and lipase (11%), and maculopapular rash (11%). Incidence of rash (grouped term) was 61%. 70 The US FDA and EMA granted regular approval to ceritinib. EGFR-mutated patients with CNS metastases, in an ongoing phase II trial (ASCEND-7), are being evaluated regarding efficacy and safety of oral ceritinib treatment in ALK-rearranged patients with brain and/or leptomeningeal metastases (NCT02336451).
Concerning the first-line setting, ceritinib showed a statistically significant and clinically meaningful improvement in PFS versus platinum-based chemotherapy in ALK þ patients included in the randomized phase III ASCEND-4 study. In the total of 376 patients randomly assigned to ceritinib (n ¼ 189) or chemotherapy (n ¼ 187), median PFS was 16.6 and 8.1 months, respectively (HR, 0.55; P < .00001).
71
The long-term efficacy of ceritinib is limited by development of resistance, mainly because of secondary ALK mutations that could predict sensitivity to third-generation ALK inhibitors (like lorlatinib). In biopsies of 103 ALK-positive patients whose disease progressed during various ALK inhibitor treatments, it was identified that each ALK inhibitor is associated with a distinct spectrum of ALK resistance mutations and that the frequency of 1 mutation, ALKG1202R, increases significantly after treatment with secondgeneration agents. 72 Ceritinib showed activity against different ALK mutations including L1196M, G1269A, I1171, and S1206Y crizotinib-resistant mutations, however, it was not active against the G1202R mutation. Furthermore, novel V1180L gatekeeper mutation and a second novel I1171T mutation identified in patients whose disease progressed during alectinib treatment conferred resistance also to crizotinib, but the sensitivity to ceritinib and other next-generation ALK TKIs is preserved in cell-line models. 73 These findings highlight the importance of repeat biopsies and genotyping after disease progression during targeted therapy treatments, particularly second-generation ALK inhibitors, to guide proper sequencing of next-generation ALK inhibitors.
Alectinib. Alectinib is a potent ALK TKI with activity against the effects of several ALK mutations that confer resistance to crizotinib (such as Thr1151_Leu1152insThr, Leu1196Met, Cys1156Tyr, Phe1174Leu, and Gly1269Ala). Unlike crizotinib, alectinib is a CNS penetrant; it is not a substrate of P-glycoprotein, a key efflux transporter located at the bloodebrain barrier. In preclinical as well as clinical investigations, alectinib was active in the CNS. [74] [75] [76] In a Japanese single-arm, open-label, phase I/II study (AF-001JP) conducted before the availability of crizotinib, alectinib 300 mg twice per day showed high activity in chemotherapy-pretreated, ALK TKI-naive patients with ALK þ NSCLC. In the primary analysis, the proportion of patients who achieved an objective response was 93.5% with 43 of 46 evaluable patients responding to treatment. 77 To assess PFS and OS, patients from the phase II part of AF-001JP were followed-up for approximately 3 years. At the updated data cutoff (September 10, 2015), alectinib seemed to be an effective treatment when administered for an extended time frame, with a 3-year PFS rate of 62%, with 25 of 46 phase II patients still receiving alectinib. 78 Fourteen patients had brain metastases at baseline: of these, 6 (43%) remained in the study without CNS and systemic progression. Overall, efficacy outcomes were similar in patients with or without CNS metastases at baseline, suggesting that alectinib would be suitable for ALK þ disease, regardless of CNS involvement. Despite the long administration time, AEs reported were still only mild to moderate in severity, with no treatment-related Grade 4 or 5 AEs. Increased blood bilirubin was the most common treatment-related AE (all grades, 36.2%). 78 On the basis of these results, a phase I/II study of alectinib was conducted in United States to establish the recommended phase II dose of the drug and examine its activity in 47 ALK-rearranged patients resistant or intolerant to crizotinib. Alectinib was well tolerated with promising antitumor activity reported in all populations (ORR, 54.5%) as well as in 21 patients with CNS metastases (ORR, 52%). On the basis of activity, tolerability, and pharmacokinetic data, alectinib 600 mg twice a day was chosen as the recommended dose for phase II. 75 These findings led to the approval of alectinib in Japan in July, 2014. 76 To further evaluate the efficacy of alectinib in the CNS, a pooled efficacy and safety analysis has been conducted on patients with CNS disease from previous phase II trials. 81 A total of 225 patients were enrolled, of whom 136 with baseline CNS disease were included in this pooled CNS analysis. Regarding previous treatments, radiotherapy was not done in approximately one-third of the patients, whereas among patients who received previous CNS radiotherapy, most of these patients had completed it >6 months before starting alectinib. This suggest that the activity observed with alectinib was unlikely related to previous radiation. Alectinib showed good CNS efficacy, with IRC CNS ORRs of 64.0% and 42.6% for patients with measurable and/or nonmeasurable CNS disease at baseline, respectively. Thirty-seven complete responses (27%) was observed for patients with measurable and/or nonmeasurable CNS disease at baseline, showing that alectinib can provide CNS benefit regardless of whether the disease is measurable according to RECIST. Of note, the activity was seen irrespective of radiation history: the response was a bit lower in patients pretreated with CNS radiotherapy compared with radiotherapy-naive (CNS ORR 35.8% vs. 58.5%, respectively), whereas a similar CNS DCR was reported (CNS DCR 86.3% vs. 82.9%, respectively). At the median follow-up of 12 months, in the overall population only 17% of the patients had CNS progressive disease, whereas only 8% of patients without baseline CNS metastases had CNS disease progression. Responses observed in the CNS were durable, with a CNS DoR of approximately 11 months, and were comparable with those observed for the overall systemic disease assessment. 81 Alectinib has the potential to be a new standard therapy for ALK þ NSCLC also in the first-line setting. Two randomized phase III trials compared alectinib (600 mg twice daily) to crizotinib in previously untreated ALK þ patients, including those with asymptomatic CNS disease (J-ALEX; n ¼ 207 patients; ALEX, n ¼ 303 patients). 82, 83 In both, alectinib showed superior efficacy and lower toxicity than crizotinib. The Japanese study met its primary end point of showing superiority of alectinib in independent review facility-assessed PFS: median PFS was 25.9 months compared with 10.2 months with crizotinib (PFS HR, 0.38; P < .0001). The superior efficacy of alectinib over crizotinib was consistent across most predefined patient subgroups, including those with brain metastases at baseline: for patients without brain metastasis at baseline (n ¼ 164), alectinib prevented CNS metastasis onset compared with crizotinib (HR, 0.19); for patients with brain metastasis at baseline (n ¼ 43), alectinib also prevented CNS progression compared with crizotinib (HR, 0.51). Grade 3 or 4 AEs occurred at a greater frequency with crizotinib than alectinib (56.7% vs. 32%, respectively). 82, 84 Similarly, in the ALEX trial alectinib showed statistically significant superiority versus crizotinib, reducing risk of progression/ death by 53% (HR, 0.47); median PFS for alectinib was not reached rather than 11.1 months in the crizotinib arm. Regarding CNS metastases, the time to CNS progression was significantly longer with alectinib (cause-specific HR, 0.16; P < .001) with an ORR of 83% versus 76% (P ¼ .09). Serious grade AEs were less frequent with alectinib (41% vs. 50% with crizotinib). 83, 85 Other New ALK Inhibitors. The activity of brigatinib and lorlatinib in patients with advanced ALK þ NSCLC highly pretreated with chemotherapy and crizotinib, has been evaluated in phase II trials. [86] [87] [88] [89] Brigatinib achieved a promising intracranial and whole-body activity in an ongoing phase I/II trial in 137 ALK þ NSCLC patients pretreated or not with crizotinib. On the basis of this result, a phase II trial (ALTA) randomly assigned (1:1) 222 patients with crizotinib-resistant ALKrearranged NSCLC (69% with brain metastases at baseline) to oral brigatinib 90 mg once daily or 180 mg once daily with a 7-day lead-in at 90 mg (180 mg once daily [with lead-in]). Brigatinib confirmed substantial whole-body and intracranial responses as well as robust PFS. The dose of 180 mg (with lead-in) showed consistently better efficacy than 90 mg (confirmed ORR of 54% vs. 45%; median PFS 12.9 vs. 9.2 months, respectively). 87 Intracranial efficacy was assessed by an IRC evaluating baseline brain images in 217 patients (153 with baseline brain metastases and 44 with measurable lesions). An ORR of 42% and 67% was reported in patients with measurable lesions at the dose of 90 mg and 180 mg, respectively. Among those with nonmeasurable lesions, response rates were 7% versus 18%. The median duration of intracranial response was not reached in either group. The median intracranial PFS was 15.6 versus 12.8 months. 88 As other ALK inhibitors, the toxicity was generally mild with few Grade 3 AEs. Gastrointestinal symptoms (nausea in 33% vs. 40%, diarrhea in 19% vs. 38%), headache (28% vs. 27%), and cough (18% vs. 34%) were the most common AEs of any grade included. The most common Grade !3 AEs were hypertension (6% vs. 6%), increased creatine phosphokinase (3% vs. 9%), pneumonia (3% vs. 5%), and increased lipase (4% vs. 3%). 88 On the basis of these results, the ALTA-1L phase III trial was designed to assess the efficacy and safety of brigatinib versus crizotinib in approximately 270 patients with advanced ALK þ NSCLC naive to TKI therapy (including ALK inhibitors; NCT02737501).
On April 28, 2017, the US FDA granted accelerated approval to brigatinib for the treatment of patients with metastatic ALK þ NSCLC who have had disease progression during or are intolerant to crizotinib treatment.
Lorlatinib is a potent next-generation ALK/ROS1 TKI active against most known resistance mutations and with an excellent penetration in the brain. In the phase I part of a phase I/II study, lorlatinib showed robust clinical activity in ALK þ or ROS1 þ advanced NSCLC patients, most of whom had CNS metastases and were heavily pretreated. The phase II part of the same study evaluated efficacy on the basis of previous ALK-TKI treatment as well as safety across all patients treated at the recommended phase II dose (100 mg once daily). Patients were enrolled into 6 expansion cohorts (EXP) on the basis of previous treatment: EXP 1 included treatment naive, EXP 2 to 5 included patients pretreated with crizotinib only or other ALK inhibitor therapy other than crizotinib or chemotherapy regimens other than 1 or more ALK inhibitors, and EXP 6 included ROS1 patients. Lorlatinib showed compelling clinical activity, with substantial intracranial activity in 82 ALK þ patients enrolled in cohorts EXP 2 to 5, pretreated with 1 or more ALK TKIs, many of whom were heavily pretreated: no clear trend in response rate was observed on the basis of number of previous ALK TKIs or ALK kinase domain mutation status. Most common AEs and Grade 3 to 4 AEs were hypercholesterolemia (90% and 17%, respectively) and hypertriglyceridemia (72% and 17%, respectively). 88 On April 27, 2017, lorlatinib was granted breakthrough therapy designation from the FDA for the treatment of patients with ALKpositive metastatic NSCLC previously treated with 1 or more ALK inhibitors.
According to different kinds of ALK resistance mutations, brigatinib has activity in G1202R, D1203N, and S1206Y/C more than crizotinib and alectinib; whereas the presence of ALK resistance mutations is highly predictive for sensitivity to lorlatinib. 72 
Expert Opinion

Consensus for Clinical Practice
The International Experts Panel Meeting on second-line treatment of NSCLC has provided a summary of recommendations for clinical practice in Table 1 .
Which Role for Immunotherapy (Anti PD-1 and AntiePD-L1) in Second-Line Treatment in Immunotherapy-Naive Wild Type NSCLC?
Recommendation
The standard of care for patients with PS 0 to 1 is nivolumab, pembrolizumab (only PD-L1 expression >1%), and atezolizumab. Of note, for nonsquamous histology, nivolumab is recommended with caution in patients at risk of early death (combined PD-L1 low or negative, progressive disease at first-line chemotherapy, PS 1). Regarding rechallenge strategy, no data are available. For patients receiving pembrolizumab as single agent, a platinum-based chemotherapy (with bevacizumab in nonsquamous histology) should be considered (V, C) For patients receiving immunotherapy with chemotherapy as first-line therapy, docetaxel with antiangiogenetics should represent a valid second-line option (V, C) For immunotherapy-naive pretreated patients with PS 0 to 1, nivolumab, pembrolizumab (only PD-L1 expression >1%) and atezolizumab are currently the standard of care. Nivolumab is recommended with caution in nonsquamous patients at risk of early death (combined PD-L1 low or negative, progressive disease at first-line chemotherapy, PS 1) (I, A). For patients not eligible for immunotherapy, docetaxel combined with ramucirumab or nindetanib (for nonsquamous histology only) can be considered treatment options as second-line therapy (V, C) A single-agent chemotherapy-docetaxel or pemetrexed in nonsquamous only-can be considered (if not used previously) in pretreated patients not eligible for immunotherapy or for docetaxel with antiangiogenetics (V, C) The role of EGFR-TKI (erlotinib) is restricted to patients unfit for other treatments (V, C) (Table 2) .
Second
Conclusion
Until a few years ago, a treatment other than single-agent chemotherapy (such as docetaxel) seemed to be utopia for patients whose disease progressed during first-line therapy. Currently, the introduction of an increasing number of drugs (such as targeted therapy and immunotherapy) has revolutionized the therapeutic strategy in clinical practice. To clarify the best sequencing of available treatments, the knowledge of the complete molecular profile is mandatory at baseline, but it seems to be crucial also at the time of disease progression. The phenotypic valuation of PD-L1 expression status has intrinsic limits, but to date it is the only tool to select patients for immunotherapy. The research of new predictive biomarkers for "tailored" immunotherapy is still ongoing, with new promising markers under valuation, such as INFg, tumor-infiltrating lymphocytes, and mutational burden. The duration of immunotherapy treatment, the rechallenge with antiePD-1 or antiePD-L1 agents in immunotherapy pretreated patients, the combination strategies (such as combinations with other immune agents or with singleagent chemotherapy or with antiangiogenetics) and the role in special patient populations (brain metastases, PS 2, elderly) represent new goals for future clinical research. In oncogenedriven tumors, the better knowledge of mechanisms of acquired resistance to earlier TKIs is leading to novel active inhibitors now available/in development. Although a long survival has been described in these patients when treated with TKIs, at present, a cure for these patients is still not available and sequential therapies are needed, focusing on T790M þ patients whose disease progressed during osimertinib treatment, on ALK þ patients whose disease progressed during first-line alectinib treatment, and on ROS1 þ patients after first-line crizotinib treatment. 
